Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Langdon

Showing results (51-60 of 180) with videos related to

Pageof 18
Sort By:
BMC Systems Biology|November 9, 2012
A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifenGalina Lebedeva, Azusa Yamaguchi, Simon P Langdon, et al.
Expert Opinion on Biological Therapy|May 15, 2010
Pertuzumab for the treatment of ovarian cancerSimon P Langdon, Dana Faratian, Yoko Nagumo, et al.
Journal of Clinical Pathology|March 14, 2012
HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysisHugh McCaughan, Inhwa Um, Simon P Langdon, et al.
British Journal of Cancer|October 1, 1996
Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumoursK E Wilson, S P Langdon, A M Lessells, et al.
Breast Cancer : Basic and Clinical Research|July 3, 2020
Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated <i>NDRG1</i>-Driven Proliferation in Triple-Negative Breast CancerAkanksha Mishra, Maria Bonello, Adam Byron, et al.
Oncotarget|August 11, 2015
A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line modelsChrysi Xintaropoulou, Carol Ward, Alan Wise, et al.
Biochemical Pharmacology|March 1, 1982
Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamineC Brindley, A Gescher, S P Langdon, et al.
Molecular Cancer Therapeutics|January 24, 2007
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingPeter Mullen, David A Cameron, Max Hasmann, et al.
Scientific Reports|October 28, 2015
Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosisWim Verleyen, Simon P Langdon, Dana Faratian, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitorsIbrahim H Kankia, Poornima Paramasivan, Matthew Elcombe, et al.
Pageof 18

Showing results (51-60 of 180) with videos related to

Sort By:
Pageof 18
BMC Systems Biology|November 9, 2012
A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifenGalina Lebedeva, Azusa Yamaguchi, Simon P Langdon, et al.
Expert Opinion on Biological Therapy|May 15, 2010
Pertuzumab for the treatment of ovarian cancerSimon P Langdon, Dana Faratian, Yoko Nagumo, et al.
Journal of Clinical Pathology|March 14, 2012
HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysisHugh McCaughan, Inhwa Um, Simon P Langdon, et al.
British Journal of Cancer|October 1, 1996
Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumoursK E Wilson, S P Langdon, A M Lessells, et al.
Breast Cancer : Basic and Clinical Research|July 3, 2020
Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated <i>NDRG1</i>-Driven Proliferation in Triple-Negative Breast CancerAkanksha Mishra, Maria Bonello, Adam Byron, et al.
Oncotarget|August 11, 2015
A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line modelsChrysi Xintaropoulou, Carol Ward, Alan Wise, et al.
Biochemical Pharmacology|March 1, 1982
Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamineC Brindley, A Gescher, S P Langdon, et al.
Molecular Cancer Therapeutics|January 24, 2007
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingPeter Mullen, David A Cameron, Max Hasmann, et al.
Scientific Reports|October 28, 2015
Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosisWim Verleyen, Simon P Langdon, Dana Faratian, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitorsIbrahim H Kankia, Poornima Paramasivan, Matthew Elcombe, et al.
Pageof 18